Background: Tumor rejection antigen P1A is tightly regulated and is restricted to immune privileged organs such as testis and some lineages of cancer cells including myeloma cells. We have studied P1A-specific cytotoxic T lymphocytes (CTL) responses in a mouse plasmacytoma (J558) model. We showed that P1A-specific CTLs could be efficiently activated in vivo and under optimal conditions, P1A-specific CTL cells can completely eliminate established large P1A+ myeloma. Recently we have successfully cloned the human P1A gene from human cancer cells. Preliminary studies suggest that human P1A is preferentially expressed in myeloma cells but not in normal human tissues. Using human-P1A expressing adenovirus to immunize HLA-A2 transgenic mice, we have found that a few A2-binding peptides can stimulate immune splenocytes to produce IFN-gamma, these epitopes can thus be potentially targeted by CTL in human cancer patients.
Description: Rabbit polyclonal to Tumor rejection antigen P1A
Immunogen: KLH conjugated synthetic peptide derived from Tumor rejection antigen P1A
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/500-1000. Predicted Mol wt: 23 kDa;
·Immunohistochemistry (Frozen/paraffin tissue section): 1/100-500;
·Immunocytochemistry: 1/200-500;
·ELISA: 1/500;
· Optimal working dilutions must be determined by the end user.
